Explore our ACCC 2020 Impact Report, the Oncology Issues, Vol.36, N.3, and our video podcast, CANCER BUZZ TV.

Industry News Archive

FDA Approves Component of Chemotherapy Regimen for ALL and LBL

On June 30, 2021, the U.S. Food and Drug Administration (FDA) approved asparaginase erwinia chrysanthemi (recombinant)-rywn as a component of a multi-agent chemotherapy regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients who are allergic to the E. coli-derived asparaginase products used most commonly for treatment.

Read the FDA announcement.

Read the Jazz Pharmaceuticals announcement.

Posted 7/1/2021

1801 Research Boulevard Suite 400
Rockville, MD 20850
Tel: 301.984.9496 | Fax: 301.770.1949
scosonline.com
Email Us